SCHEMBL24257535

SCHEMBL24257535

Cc1c(-c2cnn(-c3ccc(F)cc3)c2)cnc(C#N)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 7/20 0.45
MELK Q14680 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
DYRK1B Q9Y463 1/20 0.34
AR P10275 1/20 0.33
HTR2B P41595 1/20 0.33
MTNR1A P48039 1/20 0.33
KCNH2 Q12809 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GRM5 P41594 1/20 0.32
MAP4K4 O95819 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
JAK2 O60674 1/20 0.32
JAK3 P52333 1/20 0.32
PTK2 Q05397 1/20 0.32
AXL P30530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257502 0.88 GRM4 (0.53) GRM4MELKHTR2BMTNR1AKCNH2
SCHEMBL24257536 0.78 GRM4 (0.44) GRM4MELKKCNH2KDM4EMEN1
SCHEMBL24257531 0.78 GRM5 (0.52) GRM4HTR2BMTNR1AKCNH2KDM4E
SCHEMBL24257592 0.74 KDM5A (0.37) KDM5BIRAK4JAK2AXL
SCHEMBL30453225 0.73 NPSR1 (0.41) KCNH2KDM4EGRM5MAP4K4
SCHEMBL24257730 0.73 NPSR1 (0.41) KCNH2KDM4EGRM5MAP4K4
SCHEMBL24257766 0.71 IRAK4 (0.43) KDM5BIRAK4JAK2JAK3AXL
SCHEMBL24257513 0.70 KDM4E (0.38) KDM4EMEN1KMT2A
SCHEMBL30453043 0.70 KDM4E (0.38) KDM4EMEN1KMT2A
SCHEMBL27377074 0.69 GRM4 (0.46) GRM4MELKDYRK1BKDM4EGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 GRM4 3161/4885MELK 888/4885KDM5B 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.